NPHLA Tracker · Clinical trials (ClinicalTrials.gov)
Clinical Trial Tracker: Metabolic & Aesthetic Medicine
Clinical trials followed in metabolic and aesthetic medicine — obesity and incretin therapies, neurotoxins, dermal fillers, regenerative treatments and hair restoration — with each study’s status, phase and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 187
- Changed in 7 days
- 0
- Latest record
- Jurisdiction
- International / multiple
Records
187 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| GINEBRA: Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)NCT06790225Conditions: Bone Disease, Metabolic; Diabetes Mellitus, Type 2; Obesity and Obesity-related Medical Conditions. Interventions: Glucose-dependent Insulinotropic Polypeptide (GIP) | Completed | Not applicable | Esbjerg Hospital - University Hospital of Southern Denmark | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06790225 (opens in a new tab)Primary source | System checked NPHLA updated |
| TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC) | Not yet recruiting | Phase 2 / Phase 3 | yifang zhu | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07734792 (opens in a new tab)Primary source | System checked NPHLA updated |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis. Interventions: Survodutide; Placebo | Recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06632444 (opens in a new tab)Primary source | System checked NPHLA updated |
| DUTCH-WAIST: DUTCH Weight Control in Atrial Fibrillation StudyNCT06184633Conditions: Atrial Fibrillation; Obesity; Weight Loss. Interventions: Semaglutide 3.2 MG/ML; Placebo | Active, not recruiting | Phase 4 | Rijnstate Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06184633 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872Conditions: Type 2 Diabetes Mellitus. Interventions: RO7795081; Semaglutide; Placebo | Active, not recruiting | Phase 2 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07112872 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatideNCT07793929Conditions: End Stage Renal Disease; Renal Impairment; Obesity; Overweight. Interventions: Ribupatide | Recruiting | Phase 1 | Kailera | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07793929 (opens in a new tab)Primary source | System checked NPHLA updated |
| SWIFT: Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial CancerNCT07820358Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endo…. Interventions: Semaglutide (Wegovy) weekly injection; LNG-IUD (Progestin); Structured Weight Loss Program | Not yet recruiting | Phase 2 | The Methodist Hospital Research Institute | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07820358 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-5: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06109311 (opens in a new tab)Primary source | System checked NPHLA updated |
| GATA-3: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)NCT05254314Conditions: Asthma. Interventions: Semaglutide Pen Injector 2.4mg weekly; Placebo | Active, not recruiting | Phase 2 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05254314 (opens in a new tab)Primary source | System checked NPHLA updated |
| Elecoglipron: A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusNCT07775404Conditions: Obesity; Overweight. Interventions: Elecoglipron; Placebo | Recruiting | Phase 3 | AstraZeneca | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07775404 (opens in a new tab)Primary source | System checked NPHLA updated |
| Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979Conditions: Obesity; Overweight. Interventions: ABBV-295; Placebo | Recruiting | Phase 2 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07752979 (opens in a new tab)Primary source | System checked NPHLA updated |
| REIMAGINE 1: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174Conditions: Type 2 Diabetes. Interventions: Cagrilintide; Semaglutide; Placebo | Completed | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06323174 (opens in a new tab)Primary source | System checked NPHLA updated |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07817251 (opens in a new tab)Primary source | System checked NPHLA updated |
| Clinical Application of Stem Cell Educator Therapy in Alopecia AreataNCT04011748Conditions: Alopecia Areata; Alopecia Totalis; Alopecia Universalis. Interventions: Stem Cell Educator therapy | Active, not recruiting | Phase 2 | Throne Biotechnologies Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04011748 (opens in a new tab)Primary source | System checked NPHLA updated |
| Evidence-Based Integrated Protocol to Maximize Hair Follicle Survival in Follicular Unit Extraction (FUE)NCT07850011Conditions: Androgenetic Alopecia; Cicatricial Alopecia. Interventions: Integrated Evidence-Based FUE Protocol; Standard FUE Practice | Not yet recruiting | Not applicable | Assiut University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850011 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaNCT07849348Conditions: Obesity; Chronic Kidney Disease; Albuminuria. Interventions: Finerenone; Finerenone Placebo; Semaglutide | Not yet recruiting | Not applicable | Peking University People's Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07849348 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667Conditions: Obesity. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07011667 (opens in a new tab)Primary source | System checked NPHLA updated |
| SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNCT07850050Conditions: Obesity. Interventions: Survodutide; Placebo | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850050 (opens in a new tab)Primary source | System checked NPHLA updated |
| SCALA-TK-CM: A Retrospective Real-World Cohort StudyNCT07781371Conditions: Obesity; Type 2 Diabetes (T2D); Prediabetes; Cardiovascular Disease (CVD); Dyslipidemia; Metabolic Dysfunction-associated Steatotic Liver D…. Interventions: No treatment given | Active, not recruiting | Phase not stated | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07781371 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Conditions: Obesity; Type 2 Diabetes. Interventions: Cagrisema; Semaglutide | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07564414 (opens in a new tab)Primary source | System checked NPHLA updated |
| DEFINE: A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxinNCT03449251Conditions: Cardiovascular Diseases; Type 2 Diabetes Mellitus. Interventions: Apelin; Relaxin; Normal saline; Verapamil; LN Monomethyl arginine | Active, not recruiting | Phase 2 | Cambridge University Hospitals NHS Foundation Trust | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03449251 (opens in a new tab)Primary source | System checked NPHLA updated |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Interventions: Survodutide; Placebo matching survodutide | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850063 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRPTI Metabolic and GLP-1 Pharmacodynamic StudyNCT07850466Conditions: Overweight , Obesity. Interventions: TRPTI; Placebo | Not yet recruiting | Phase 4 | RDC Clinical Pty Ltd | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850466 (opens in a new tab)Primary source | System checked NPHLA updated |
| EryAdo: Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in AdolescentsNCT04966299Conditions: Insulin Resistance; Glucose Tolerance; Body Composition; Gastrointestinal Tolerance; Thrombocyte Aggregation; Blood p-Selectin; Blood Eryth…. Interventions: Erythritol; Sucrose; Glucose; Fructose; Xylitol; Water | Active, not recruiting | Not applicable | University Hospital, Basel, Switzerland | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04966299 (opens in a new tab)Primary source | System checked NPHLA updated |
| STAY-LEAN: Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)NCT06854614Conditions: Obesity. Interventions: Comprehensive weight loss; Enhanced lifestyle changes; Tirzepatide; Naltrexone-Bupropion; Phentermine-Topiramate; Semag… | Active, not recruiting | Phase 4 | The Cleveland Clinic | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06854614 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285Conditions: Overweight; Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07253285 (opens in a new tab)Primary source | System checked NPHLA updated |
| WEgovy Real World Assessment of Weight Loss in KoreaNCT07280221Conditions: Obesity. Interventions: Semaglutide | Enrolling by invitation | Phase not stated | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07280221 (opens in a new tab)Primary source | System checked NPHLA updated |
| Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialNCT03596450Conditions: Diabetes Mellitus, Type 2. Interventions: Semaglutide; Standard of care | Completed | Phase 4 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03596450 (opens in a new tab)Primary source | System checked NPHLA updated |
| Real-World Patient and Physician Experience With Semaglutide Across Six Emerging MarketsNCT07850765Conditions: Overweight; Obesity. Interventions: Semaglutide | Completed | Phase not stated | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850765 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864Conditions: Obesity. Interventions: survodutide; Placebo | Completed | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06077864 (opens in a new tab)Primary source | System checked NPHLA updated |
| REDEFINE 1: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796Conditions: Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05567796 (opens in a new tab)Primary source | System checked NPHLA updated |
| AnteAGE Exosomes and PEARL Multiplier With Microneedling for Facial Skin QualityNCT07849205Conditions: Skin Aging; Skin Quality. Interventions: Mechanical microneedling; AnteAGE Exosomes and PEARL Multiplier; AnteAGE Homecare Regimen | Completed | Not applicable | Cellese Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07849205 (opens in a new tab)Primary source | System checked NPHLA updated |
| AnteAGE Biosomes With Radiofrequency Microneedling for Facial Skin RejuvenationNCT07849556Conditions: Skin Aging; Facial Rhytides; Skin Tone. Interventions: AnteAGE Biosome Treatment Solution; Radiofrequency Microneedling; AnteAGE Homecare Regimen | Completed | Not applicable | Cellese Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07849556 (opens in a new tab)Primary source | System checked NPHLA updated |
| Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in ObesityNCT06771115Conditions: Obesity. Interventions: Placebo; VTX3232 30 mg; Placebo in combination with semaglutide; VTX3232 30 mg in combination with semaglutide | Completed | Phase 2 | Zomagen Biosciences Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06771115 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLDNCT07527910Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Interventions: ALN-PNP; Tirzepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07527910 (opens in a new tab)Primary source | System checked NPHLA updated |
| TOLEDDO: Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"NCT05305794Conditions: Double Diabetes. Interventions: Insulin + semaglutide treatment; Usual insulin treatment; Biological check-up | Recruiting | Phase 3 | Centre Hospitalier Universitaire Dijon | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05305794 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500Conditions: Obesity; Overweight and/or Obesity; Overweight; Treatment Of Obesity. Interventions: Semaglutide; Tirzepatide; Berobenatide | Not yet recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07845500 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571Conditions: Obesity; Overweight. Interventions: LY3841136; Tirzepatide; Placebo | Completed | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06603571 (opens in a new tab)Primary source | System checked NPHLA updated |
| TELWA: Probiotics in Obese Patients Treated With GLP-1 Receptor AgonistsNCT07847593Conditions: Obesity (Disorder); GLP-1 Receptor Agonist Treatment; Probiotic Intervention; Diabetes Mellitus Type 2. Interventions: Four-strain probiotic formulation; Maltodextrin (Placebo) | Completed | Not applicable | Nordic Biotic Sp. z o.o. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07847593 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese PatientsNCT07847515Conditions: Obesity / Overweight. Interventions: Tirzepatide | Not yet recruiting | Phase not stated | Nanjing First Hospital, Nanjing Medical University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07847515 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLYCOTIME: Precise Eating Time to Improve Glycemic Control and Cardiometabolic Health in Prediabetes and DiabetesNCT07171281Conditions: Prediabetes; Type 2 Diabetes; Obesity &Amp; Overweight. Interventions: Early Time-Restricted Eating; Late Time-Restricted Eating | Recruiting | Not applicable | German Institute of Human Nutrition | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07171281 (opens in a new tab)Primary source | System checked NPHLA updated |
| TIRZE-PAP: Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness TrialNCT07846865Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Interventions: Continuous Positive Airway Pressure; Tirzepatide | Not yet recruiting | Phase 2 / Phase 3 | Woolcock Institute of Medical Research | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07846865 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesNCT07846033Conditions: Obese Adults. Interventions: SC VK3019; Matching placebo | Recruiting | Phase 1 | Viking Therapeutics, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07846033 (opens in a new tab)Primary source | System checked NPHLA updated |
| SILENCED: Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide TreatmentNCT07171723Conditions: Obesity &Amp; Overweight. Interventions: Liver-Expressed Antimicrobial Peptide 2 (LEAP2); Placebo (saline) | Completed | Phase 1 / Phase 2 | University Hospital, Gentofte, Copenhagen | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07171723 (opens in a new tab)Primary source | System checked NPHLA updated |
| PROTIME: PROTeIn-rich Meals to Control GlucoseNCT06382480Conditions: Overweight; Obesity; Prediabetes; Type 2 Diabetes. Interventions: Diet with specific macronutrient composition. | Active, not recruiting | Not applicable | German Institute of Human Nutrition | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06382480 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or ObesityNCT07724340Conditions: Adults With Overweight/Obesity and Type 2 Diabetes. Interventions: AT673 low dose; AT673 high dose; Placebo | Active, not recruiting | Phase 2 | Antag Therapeutics | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07724340 (opens in a new tab)Primary source | System checked NPHLA updated |
| NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World StudyNCT07846956Conditions: Non-arteritic Anterior Ischemic Optic Neuropathy Obesity; Obesity. Interventions: GLP-1 Receptor Agonist Therapy | Not yet recruiting | Phase not stated | Istanbul Saglik Bilimleri University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07846956 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightNCT07845578Conditions: Obesity; Overweight. Interventions: Semaglutide; Placebo semaglutide; Paracetamol | Not yet recruiting | Phase 1 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07845578 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Conditions: Overweight or Obesity. Interventions: Olatorepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07685808 (opens in a new tab)Primary source | System checked NPHLA updated |
| SEMAFORCRANIO: SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsNCT07845994Conditions: Craniopharyngioma, Child. Interventions: Semaglutide (Wegovy) weekly injection; Placebo weekly Injection | Not yet recruiting | Phase 3 | University Hospital, Angers | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07845994 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) for two broad searches — obesity and incretin therapies, and aesthetic and regenerative medicine (botulinum toxin, dermal fillers, polynucleotides, exosomes, platelet-rich plasma) — and for every topic with a trial query, on the schedule set in the Source Registry. Each study is stored with its registry fields as published. Changes in overall status and newly posted results are recorded with the date the pipeline detected them.
This tracker lists every tracked study whose last registry update falls within the past 365 days, newest first. Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch dated within the last 365 days.
What does it cover?
Studies on ClinicalTrials.gov — from the United States and other countries — that match the configured searches, from the date tracking began. Studies registered elsewhere, described with other terms, or not updated in the last year are not included.
What are its limitations?
Registry data is supplied by sponsors and may be incomplete or out of date. Inclusion reflects search terms, not clinical importance. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.